Literature DB >> 19740406

Three cases of severe hepatic impairment caused by erlotinib.

Yi-Sheng Huang, She-Juan An, Zhi-Hong Chen, Yi-Long Wu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19740406      PMCID： PMC2766488          DOI： 10.1111/j.1365-2125.2009.03459.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  Genetic polymorphisms of CYP2D6 in Chinese mainland.

Authors:  Ling Ji; Shixiu Pan; Jianmin Wu; Jacqueline Marti-Jaun; Martin Hersberger
Journal:  Chin Med J (Engl)       Date:  2002-12       Impact factor: 2.628

2.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

4.  Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations.

Authors:  M Kitada; T Kamataki; K Itahashi; T Rikihisa; Y Kanakubo
Journal:  Biochem Pharmacol       Date:  1987-02-15       Impact factor: 5.858

5.  Novel mutations of CYP3A4 in Chinese.

Authors:  K P Hsieh; Y Y Lin; C L Cheng; M L Lai; M S Lin; J P Siest; J D Huang
Journal:  Drug Metab Dispos       Date:  2001-03       Impact factor: 3.922

Review 6.  Preclinical studies with Erlotinib (Tarceva).

Authors:  Robert W Akita; Mark X Sliwkowski
Journal:  Semin Oncol       Date:  2003-06       Impact factor: 4.929

7.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

Authors:  G Danan; C Benichou
Journal:  J Clin Epidemiol       Date:  1993-11       Impact factor: 6.437

8.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

Authors:  Ulrich Gatzemeier; Anna Pluzanska; Aleksandra Szczesna; Eckhard Kaukel; Jaromir Roubec; Flavio De Rosa; Janusz Milanowski; Hanna Karnicka-Mlodkowski; Milos Pesek; Piotr Serwatowski; Rodryg Ramlau; Terezie Janaskova; Johan Vansteenkiste; Janos Strausz; Georgy Moiseevich Manikhas; Joachim Von Pawel
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

9.  Fulminant hepatic failure secondary to erlotinib.

Authors:  Weitian Liu; Frederick L Makrauer; Amir A Qamar; Pasi A Jänne; Robert D Odze
Journal:  Clin Gastroenterol Hepatol       Date:  2007-07-10       Impact factor: 11.382

10.  Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.

Authors:  Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna R Hollis; Lionel D Lewis; Hedy L Kindler; John L Marshall; Miguel A Villalona-Calero; Martin J Edelman; Raymond J Hohl; Stuart M Lichtman; Mark J Ratain
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544
View more
  2 in total

1.  Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy.

Authors:  She-Juan An; Yi-Sheng Huang; Zhi-Hong Chen; Jian Su; Yan Yang; Jian-Guang Chen; Hong-Hong Yan; Qiu-Xiong Lin; Jin-Ji Yang; Xue-Ning Yang; Qing Zhou; Xu-Chao Zhang; Yi-Long Wu
Journal:  Med Oncol       Date:  2011-04-03       Impact factor: 3.064

2.  Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis.

Authors:  Franziska Paech; Jamal Bouitbir; Stephan Krähenbühl
Journal:  Front Pharmacol       Date:  2017-06-14       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.